KRN7000 being investigated in cancer research:

Colorectal cancer research

Head and neck tumor research

Leukemia research

Lung cancer research

Lymphoma research

Melanoma research

Multiple myeloma research

Direct incorporation of the NKT-cell activator α-galactosylceramide into a recombinant Listeria monocytogenes improves breast cancer vaccine efficacy

Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model

Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses

Allogeneic DCG promote lung NK cell activation and antitumor effect after invariant NKT cell activation

Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma

Altered Invariant Natural Killer T cell Subsets and its Functions in Patients with Oral Squamous Cell Carcinoma

CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses

Antitumor immunity produced by the liver Kupffer cells, NK cells, NKT cells, and CD8 CD122 T cells

Role of γδ T cells in α-galactosylceramide-mediated immunity

Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses

Activation of natural killer T cells by NK-4, a criptocyanine dye

Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer

Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α

Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy

Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine

Regulation of secondary antigen-specific CD8(+) T-cell responses by natural killer T cells

An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity

Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model

Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients

Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy

A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer

Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection

α-Galactosylceramide activates antitumor immunity against liver tumor

IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses

The contrasting roles of NKT cells in tumor immunity

Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer

Combining Carbon Ion Radiotherapy and Local Injection of α-Galactosylceramide-Pulsed Dendritic Cells Inhibits Lung Metastases in an In Vivo Murine Model

Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials

A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapy

DNA vaccine with alpha-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells

Human leukemic cells loaded with alpha-galactosylceramide (alpha-GalCer) activate murine NKT cells in situ

PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells

Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand

Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide

KRN7000, a novel immunomodulator, and its antitumor activities

Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity

Depletion of CD4+CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model

Interleukin-2 gene transfer potentiates the alpha-galactosylceramide-stimulated antitumor effect by the induction of TRAIL in NKT and NK cells in mouse models of subcutaneous and metastatic carcinoma

Antitumor Effect of Alpha-Galactosylceramide (KRN7000) on Spontaneous Hepatic Metastases Requires Endogenous Interleukin 12 in the Liver

Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation

The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy

Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity

Alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors

Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells

Application of natural killer T cells in antitumor immunotherapy

Alpha-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis

Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice

Invariant natural killer T cell-based immunotherapy for cancer

Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells

In vitro anti-tumour activity of α-galactosylceramide-stimulated human invariant Vα24+NKT cells against melanoma

Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo

Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells

Modulation of human Valpha24(+)Vbeta11(+) NKT cells by age, malignancy and conventional anticancer therapies

Harnessing CD1d-restricted T cells toward antitumor immunity in humans

Natural killer T cell-mediated antitumor immune responses and their clinical applications

Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells

Cutting Edge: Inhibition of Experimental Tumor Metastasis by Dendritic Cells Pulsed with Alpha-Galactosylceramide

Effects of alpha-galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human Va24+ Vb11+ T cells

Invariant Natural Killer T Cells in Immune Surveillance and Tumor Immunotherapy: Perspectives and Potentials

Potent Anti-tumor effects of Combination therapy using Interleukin-23 and .ALPHA.-galactosylceramide

alpha-Galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity

alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor

Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells

Therapeutic activation of V alpha 24(+)V beta 11(+) NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity

Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice

Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms

Alpha-galactosylceramide: potential immunomodulatory activity and future application

Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide

Natural killer T cell ligand alpha-galactosylceramide inhibited lymph node metastasis of highly metastatic melanoma cells

IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide

Role of NKT cells to assist priming of antigen-specific T-cell responses

Active immunization against cancer with dendritic cells: The near future

Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells

Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells

Enhancing effects of agelasphin-11 on natural killer cell activities of normal and tumor-bearing mice

Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells

Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells

A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model

Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000

No inhibition of urinary bladder carcinogenesis in rats with intravesical instillation of alpha-galactosylceramide

Antitumor Activities of KRN7000 in NS-1 Myeloma-Bearing Mice

A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors

Role of NKT cells and alpha-galactosyl ceramide

Population pharmacokinetics of the novel anticancer agent KRN7000

In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma

KRN7000 inhibit hepatic metastasis of pancreatic cancer

Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells

Antitumor activities of combined treatment with a novel immunomodulator, (2S,3S,4R)-1-O-(alpha-D-Galactopyranosyl)-2-(N-Hexacosanoylamino)-1,3,4 - octadecanetriol (KRN7000), and radiotherapy in tumor-bearing mice

A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance

Natural killer T cell-mediated immunotherapy for malignant diseases

Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities

Presentation of alpha-galactosylceramide by murine CD1d to natural killer T cells is facilitated by plasma membrane glycolipid rafts

Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide

Tumor-infiltrating effector cells of alpha-galactosylceramide-induced antitumor immunity in metastatic liver tumor

Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles

CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses

Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells

Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide

Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide

In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers

Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells

A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas

CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver

Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells

Back to top

 

New 7DW8-5 glycolipid

7DW8-5

Now available 7DW8-5 glycolipid derivative of Alpha-GalCer for human and mice iNKT immunoresearch

 

Meet Funakoshi Company
at the following meetings:

AACR
Washington DC
April 1-5, 2017

The 11th Annual Meeting of Japanese Society for Epigentics
Tokyo, Japan
May 22-23, 2017

The 36th Annual Meeting of Japanese Association of Forensic Toxicology

The 21st Annual Meeting of Japanese Assocation of Cancer Immunology
Chiba, Japan
June 28-30, 2017

The Japanese Society for Genome Editing
Osaka, Japan
June 28-30, 2017

The 76th Annual Meeting of the Japanese Cancer Association
Yokohama, Japan
September 28-30, 2017

NIH Festival
Bethesda, Maryland
September 2017

ASCB
Philadelphia, PA
December 2-6, 2017